In this context, a recent study in murine models of HFpEF demonstrated that empagliflozin, an SGLT2 inhibitor recommended for the treatment of HFpEF, reduces oxidative stress by inhibiting pro-inflammatory signalling in the STAT1 signalling pathway [42], further studies being needed to determine the extent to which it can reduce the risk of developing this type of heart failure in patients with chronic proliferative neoplasms. This evidence concerns the gene SLC5A2 and heart failure.